Cipla Ltd

Cipla Ltd. announced that Aspergen Limited, a 60:40 joint venture with Kemwell Biopharma Private Limited, has acquired 100% stake in Aspergen Inc., USA, from Cipla (EU) Limited and Kemwell Biopharma UK Limited, making Aspergen Inc., USA a wholly owned subsidiary of Aspergen Limited, India; the restructuring was undertaken to rationalize and simplify the group structure and results in no change to Cipla’s economic interest in Aspergen Inc., USA.

Cipla Ltd. announced that its Operations and Administrative Committee has allotted 5,281 fully paid-up equity shares of INR 2 each under the Employee Stock Option Scheme 2013 -A and the Cipla Employee Stock Appreciation Rights Scheme 2021, increasing the company’s issued, subscribed and paid-up share capital to INR 1,61,57,16,894 comprising of 80,78,58,447 equity shares.

A court order has paved the way for the amalgamation of a wholly-owned subsidiary into its parent company, streamlining the merger process under Company Application No. 114/2026. The scheme, involving the Transferor Company merging into the Transferee Company, does not necessitate the issuance of new shares or negatively impact creditors, leading the court to dispense with shareholder and creditor meetings of the Transferee Company, citing precedents like *Mahaamba Investments Limited*. While meetings are waived, the Transferee Company must still provide notice to shareholders, creditors, and regulatory bodies via various channels, allowing a 30-day period for objections. The Applicant Companies are also required to file details regarding corporate guarantees, pending legal cases, and letters of credit, and post the scheme on their website, followed by an affidavit of service within 10 working days.

Cipla Ltd. announced that its Operations and Administrative Committee has allotted 7,850 fully paid-up equity shares of Rs 2 each under the Employee Stock Option Scheme 2013 -A and the Cipla Employee Stock Appreciation Rights Scheme 2021, increasing the company's issued, subscribed and paid-up share capital to Rs 1,61,57,06,332 comprising of 80,78,53,166 equity shares of face value Rs 2 each.

The board of Cipla at its meeting held on 23 July 2026 has approved the following: Transition of Ashish Adukia, Global Chief Financial Officer, to internal business leadership role. Consequent to such transition, Ashish Adukia has relinquished the position as the Global Chief Financial Officer and Key Managerial Personnel (KMP) of the Company with effect from close of business hours of 23 July 2026. Appointment of Dinesh Jain, Chief ' Corporate Finance, as Global Chief Financial Officer and KMP with effect from 24 July 2026.

Cipla has granted 24,709 stock options and employee stock appreciation rights on 23 July 2026.

Revenue from operations increased 3.51% YoY to Rs 7,077.02 crore in the quarter ended 30th June 2026. Profit before tax (PBT) fell 38.87% YoY to Rs 1,081.93 crore in Q1 FY27. EBITDA stood at Rs 1,192 crore, down 32.96% compared with Rs 1,778 crore in Q1 FY26, while the EBITDA margin contracted to 16.7% from 25.6% a year earlier. On the business front, the India business remained the key growth driver, with revenue rising 12% year-on-year to Rs 3,452 crore. Revenue from One Africa- comprising South Africa, North Africa, Sub-Saharan Africa and Cipla Global Access - also grew 12% to Rs 977 crore, while Emerging Markets and Europe recorded 16% growth to Rs 999 crore. However, revenue from North America declined 21% year-on-year to Rs 1,532 crore, while the API and other business segment fell 28% to Rs 160 crore during the quarter. During the quarter, research and development (R&D) expenditure increased 12.3% year-on-year to Rs 486 crore, accounting for 6.8% of sales, driven by higher product filings and ongoing development initiatives. Achin Gupta MD and Global CEO, Cipla, said, 'We are pleased to share that we continue to make considerable progress across our focused markets. In Q1FY27, we delivered global revenues of Rs 7,119 crore. Our One-India business grew at solid 12% YoY. Branded Prescription business delivered a robust growth, with key therapies outpacing the market, Trade Generics recorded healthy growth and Anchor brands of Consumer Health Business maintained leadership position. The US business posted a revenue of $162 million during the quarter. We expect continued sequential growth in North America, supported by upcoming product pipeline. South Africa private business continued to grow faster than the market. Emerging Markets and Europe continued its growth trajectory with revenue growth of 5% YoY in USD terms on the back of deep market focus strategy. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front.' Cipla is a global pharmaceutical company with operations across India, South Africa, North America and other regulated and emerging markets. The company focuses on complex generics and therapies including respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments. Cipla operates 46 manufacturing facilities globally, producing more than 1,500 products across over 80 markets.Powered by Capital Market - Live

Net profit of Cipla declined 39.19% to Rs 789.05 crore in the quarter ended June 2026 as against Rs 1297.62 crore during the previous quarter ended June 2025. Sales rose 3.51% to Rs 7077.02 crore in the quarter ended June 2026 as against Rs 6837.04 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales7077.026837.04 4 OPM %16.8526.01 - PBDT1386.172022.65 -31 PBT1081.931769.93 -39 NP789.051297.62 -39 Powered by Capital Market - Live

Cipla announced that an inspection was conducted by the United States Food and Drug Administration (USFDA) at the manufacturing facility of InvaGen Pharmaceuticals Inc. (wholly owned subsidiary of the company) located in Central Islip, Long Island, New York, USA, from 13 July 2026 to 17 July 2026 (EDT). The inspection was a routine current Good Manufacturing Practices (cGMP) Inspection. On conclusion of the inspection, the company has received 1 (one) inspectional observation in Form 483.

Cipla Ltd gained for a fifth straight session today. The stock is quoting at Rs 1476.6, up 2.53% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.46% on the day, quoting at 23944.45. The Sensex is at 76716.34, down 0.5%. Cipla Ltd has risen around 6.21% in last one month. Meanwhile, Nifty Pharma index of which Cipla Ltd is a constituent, has risen around 4.4% in last one month and is currently quoting at 24969.5, up 1.25% on the day. The volume in the stock stood at 20.59 lakh shares today, compared to the daily average of 15.8 lakh shares in last one month. The benchmark June futures contract for the stock is quoting at Rs 1472.9, up 2.22% on the day. Cipla Ltd is down 1.95% in last one year as compared to a 6.16% drop in NIFTY and a 14.71% drop in the Nifty Pharma index.The PE of the stock is 33.8 based on TTM earnings ending March 26.Powered by Capital Market - Live